Citations

Clear

959 citation(s) found for "Service, F J".

Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline
Wyckoff, Jennifer , Lapolla, A., Asias-Dinh, Bernadette , Barbour, Linda A. , Brown, Florence M. , Catalano, Patrick , Corcoy, Rosa , Drobycki, Nancy, Kautzky‐Willer, Alexandra , Stephenson-Gray, Melanie, Tabák, Ádám G. , Weatherup, Emily, Zera, Chloe , Ospina, Naykky Singh , Ospina, Naykky Singh , Corrigan, Maureen D. , Wyckoff, Jennifer A , Kautzky-Willer, Alexandra , Murad, M Hassan , Tabák, Adam G , Singh Ospina, Naykky , Lapolla, Annunziata, Renzo, Gian Carlo Di , Murad, M. Hassan , Stephenson-Gray, Melanie

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | May 14, 2025 | Volume: 110 | Issue: 9 | Pages: 2405-2452

10.1210/clinem/dgaf288 | PMID 40652453 Get It

Abstract Background Preexisting diabetes (PDM) increases the risk of maternal and perinatal mortality and morbidity. Reduction of maternal hyperglycemia prior to and during pregnancy can reduce these risks. Despite compelling evidence that preconception care (PCC), which includes achieving strict glycemic goals, reduces the risk of congenital malformations and other adverse pregnancy outcomes, only a minority of individuals receive PCC. Suboptimal pregnancy outcomes demonstrated in real-world data highlight the need to further optimize prenatal glycemia. New evolving technology shows promise in helping to achieve that goal. Dysglycemia is not the only driver of poor pregnancy outcomes in PDM. The increasing impact of obesity on pregnancy outcomes underscores the importance of optimal nutrition and management of insulin sensitizing medications during prenatal care for PDM. Objective To provide recommendations for the care of individuals with PDM that lead to a reduction in maternal and neonatal adverse outcomes. Methods The Guideline Development Panel (GDP) composed of a multidisciplinary panel of clinical experts, along with experts in guideline methodology and systematic literature review, identified and prioritized 10 clinically relevant questions related to the care of individuals with diabetes before, during and after pregnancy. The GDP prioritized randomized controlled trials (RCTs) evaluating the effects of different interventions (eg, PCC, nutrition, treatment options, delivery) during the reproductive life cycle of individuals with diabetes, including type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Systematic reviews queried electronic databases for publications related to these 10 clinical questions. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology was used to assess the certainty of evidence and develop recommendations. The approach incorporated perspectives from 2 patient representatives and considered patient values, costs and resources required, acceptability and feasibility, and impact on health equity of the proposed recommendations. Results In individuals with diabetes mellitus who have the possibility of becoming pregnant, we suggest asking a screening question about pregnancy intention at every reproductive, diabetes, and primary care visit. Screening for pregnancy intent is also suggested at urgent care/emergency room visits when clinically appropriate (2 | ⊕OOO). This was suggested based on indirect evidence demonstrating a strong association between PCC and both reduced glycated hemoglobin (HbA1c) at the first prenatal visit and congenital malformations. In individuals with diabetes mellitus who have the possibility of becoming pregnant, we suggest use of contraception when pregnancy is not desired (2 | ⊕⊕OO). This was suggested based on indirect evidence in women with diabetes, where PCC—including contraception as a key component—showed a clinically significant association with improvements in first-trimester HbA1c and the rate of congenital malformations, together with indirect evidence from the general population regarding the reduction of unplanned pregnancies and pregnancy terminations with the use of contraception. In individuals with T2DM, we suggest discontinuation of glucagon-like peptide-1 receptor agonist (GLP-1RA) before conception rather than discontinuation between the start of pregnancy and the end of the first trimester (2 | ⊕OOO). This was suggested based on limited data on risk of exposure to GLP-1RA receptor agonists during pregnancy. In pregnant individuals with T2DM already on insulin, we suggest against routine addition of metformin (2 | ⊕OOO). This was suggested based on the GDP judgment that the benefit of adding metformin to insulin to achieve decrease in rates of large for gestational age infants did not outweigh the potential harm of increasing the risk of small for gestational age infants or adverse childhood outcomes related to changes in body composition. In individuals with PDM, we suggest either a carbohydrate-restricted diet (<175 g/day) or usual diet (>175 g/day) during pregnancy (2 | ⊕OOO). This was suggested based on the GDP judgment that the available evidence was limited and very indirect, resulting in significant uncertainty about the net benefits or harms. As such, the evidence was insufficient to support a recommendation either for or against a carbohydrate intake cutoff of 175 g/day. In pregnant individuals with T2DM, we suggest either the use of a continuous glucose monitor (CGM) or self-monitoring of blood glucose (SMBG) (2 | ⊕OOO). There is lack of direct evidence supporting superiority of CGM use over SMBG for T2DM during pregnancy. There is indirect evidence supporting improved glucometrics with the use of CGM for individuals with T2DM outside of pregnancy, substantial improvements in neonatal outcomes for individuals with T1DM using CGM during pregnancy and the potential for decreasing adverse pregnancy outcomes with improved glucometrics in individuals with T2DM. In individuals with PDM using a CGM, we suggest against the use of a single 24-hour CGM target <140 mg/dL (7.8 mmol/L) in place of standard-of-care pregnancy glucose targets of fasting <95 mg/dL (5.3 mmol/L), 1-hour postprandial <140 mg/dL (7.8 mmol/L), and 2-hour postprandial < 120 mg/dL (6.7 mmol/L) (2 | ⊕OOO). This was suggested based on indirect evidence that associated adverse pregnancy outcomes with a fasting glucose > 126 mg/dL (7 mmol/L). In individuals with T1DM who are pregnant, we suggest the use of a hybrid closed-loop pump (pump adjusting automatically based on CGM) rather than an insulin pump with CGM (without an algorithm) or multiple daily insulin injections with CGM (2 | ⊕OOO). This was suggested based on a meta-analysis of RCTs which demonstrated improvement in glucometrics with increased time in range (MD +3.81%; CI −4.24 to 11.86) and reduced time below range (MD −0.88%; 95% CI: −2.04 to 0.27) with the use of hybrid closed-loop pump technology. In individuals with PDM, we suggest early delivery based on risk assessment rather than expectant management (2 | ⊕OOO). This was suggested based on indirect evidence that risks may outweigh benefits of expectant management beyond 38 weeks gestation and that risk assessment criteria may be useful to inform ideal delivery timing. In individuals with PDM (including those with pregnancy loss or termination), we suggest postpartum endocrine care (diabetes management), in addition to usual obstetric care (2 | ⊕OOO). As the postpartum period frequently overlaps with preconception, this was suggested based on indirect evidence demonstrating a strong association between PCC and both reduced HbA1c at the first prenatal visit and congenital malformations. Conclusion The data supporting these recommendations were of very low to low certainty, highlighting the urgent need for research designed to provide high certainty evidence to support the care of individuals with diabetes before, during, and after pregnancy. Investment in implementation science for PCC is crucial to prevent significant mortality and morbidity for individuals with PDM and their children. RCTs to further define glycemic targets in pregnancy and refinement of emerging technology to achieve those targets can lead to significant reduction of harm and in the burden of diabetes care. Data on optimal nutrition and obesity management in pregnancy are lacking. More research on timing of delivery in women with PDM is also needed.
Development of a Patient Education Pathway for a Psychiatric Nurse Consult Service
Kuntz, Madeline, Linden, Tracy, Kinstler, Daniel Paul, Forsyth, Diane McNally, Forsyth, Diane, Linden, Tracy

Mayo Clinic

Journal of Psychosocial Nursing and Mental Health Services | May 13, 2025 | Volume: 63 | Issue: 11 | Pages: 15-21

10.3928/02793695-20250505-01 | PMID 40359447 Get It

Purpose: The current quality improvement project aimed to improve functionality within a psychiatric consult liaison nurse (PCLN) service through implementation of an educational pathway. Method: Pre- and postintervention qualitative interviews were conducted with eight PCLNs, and themes were generated via content analysis. Quantitative surveys were also conducted, and data were analyzed using means and standard deviations. Paired t tests were used to test for significance. Results: Qualitative results identified five themes: Flexibility vs. Uncertainty , Ambiguity vs. Direction , Structured vs. Unstructured Education , Efficiency/Time Management , and Communication . Quantitative surveys indicated the intervention improved the consistency of the psychoeducation provided ( p = 0.03) and enhanced the structure of the PCLN role ( p = 0.04). The intervention did not significantly improve communication between PCLNs and medical–surgical nurses. Conclusion: Qualitative findings showed that the educational pathway improved efficiency, time management, and communication, and quantitative findings showed it can help with consistency and structure to the role. Implementing an educational pathway for PCLNs is feasible and effective for health care systems.
Matching Patients with Surgeons: Heterogeneous Effects of Surgical Volume on Surgery Duration
Pourghannad, Behrooz , Wang, Guihua

Mayo Clinic

Manufacturing & Service Operations Management | May 13, 2025 | Volume: 27 | Issue: 4 | Pages: 1037-1052

10.1287/msom.2023.0019 Get It

Problem definition: We study how to leverage patient-specific information to improve a hospital’s operational efficiency. We use abdominal surgery as the clinical setting and study the heterogeneous effects of surgical volume on surgery duration. We develop a framework for using patient-specific information by addressing three important questions: (1) Is the effect of surgical volume heterogeneous across patients with different features? (2) If so, how could patient-specific information that captures the heterogeneous effects of surgical volume on surgery duration be generated? (3) What is the value of patient-specific information in helping a hospital improve its operational efficiency? Methodology/results: Using an instrumental variable approach to address potential endogeneity issues, we first use a regression model to show that the average effect of surgical volume on surgery duration is significant. Then, we use a regression model with interaction terms to show that the effect of surgical volume is heterogeneous. After that, we apply an instrumental variable forest approach to obtain patient-specific volume effects. Finally, we use patient-specific volume effects and an optimization model to assess the potential value of patient-specific information in improving a hospital’s operational efficiency. We find the that total duration of surgeries could be reduced by 2.5%–8.9% if patient-specific volume effects are considered. Managerial implications: This study provides a framework for understanding treatment effect heterogeneity and using patient-specific information to improve a hospital’s operational efficiency. We provide empirical evidence that the effect of surgical volume is heterogeneous and address the challenges of estimating heterogeneous effects for different patients. Our framework can help hospital administrators to better match patients with surgeons, improving a hospital’s operational efficiency. Supplemental Material: The online appendix is available at https://doi.org/10.1287/msom.2023.0019 .
Arrhythmogenic cardiomyopathy diagnosis and management: a systematic review of clinical practice guidelines and recommendations with insights for future research
Iezzi, Lorena , Sorella, Anna, Galanti, Kristian , Gallina, Sabina , Lopes, Luís R. , Ricci, Fabrizio , Khanji, Mohammed Y , Chahal, Anwar A, Bauce, Barbara , Ricci, Fabrizio , Khanji, Mohammed Yunus , Lopes, Luis Rocha , Chahal, C. Anwar A. , Cipriani, Alberto , Providência, Rui , Ricci, Fabrizio

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | May 12, 2025 | Volume: 11 | Issue: 7 | Pages: 1033-1069

10.1093/ehjqcco/qcaf029 | PMID 40386976 Get It

Abstract Arrhythmogenic cardiomyopathy (ACM) is addressed in international guidelines and expert consensus statements. To assist clinicians in their routine practice and support decision-making, we performed a systematic review of the most relevant guidelines and recommendations for ACM diagnosis and management. Our search, covering MEDLINE, EMBASE, and resources from scientific societies over the last 10 years, identified two guidelines and three consensus statements that met rigorous inclusion criteria for detailed analysis. In the examined documents, key areas of agreement included the critical role of cardiac imaging for initial diagnosis and ongoing monitoring, genetic testing in index patients, ventricular arrhythmia management, catheter ablation indications, heart failure treatment strategies, and exercise recommendations. However, significant differences were found in definitions and diagnostic criteria for ACM, interpretation of phenocopies, management of family members, and criteria for implantable cardioverter defibrillator implantation. Additional discrepancies emerged regarding the role of multidisciplinary teams, non-cardiac surgical considerations, atrial fibrillation management, and reproductive issues. Crucially, there remain considerable gaps in evidence, especially in areas such as the management and follow-up of patients with potential or borderline ACM diagnoses, as well as the care of their relatives. The clinical implications of genetic findings, along with the clinical management of left-dominant, biventricular phenotypes, and hot phases of disease, are also insufficiently addressed. Furthermore, a critical shortfall is the lack of externally validated risk assessment tools to guide clinical decision-making. Bridging these gaps could help guiding future research and guideline development towards improving patient outcomes.
Targeting the Tumor and the Immune System in Smoldering Multiple Myeloma
Maura, Francesco , Bergsagel, P. Leif , Bergsagel, P. Leif , Maura, Francesco

Mayo Clinic

New England Journal of Medicine | May 7, 2025 | Volume: 392 | Issue: 18 | Pages: 1858-1860

10.1056/nejme2504273 | PMID 40334161 Get It

HOPE Experience Essentials: The Next Generation of Service Standards at Mayo Clinic
Packard, Jennifer, Welch, Thomas, Munson, Karee, Leighton, Jonathan A. , Packard, Jennifer, Eliáš, Richard

Mayo Clinic

Patient Experience Journal | May 1, 2025 | Volume: 12 | Issue: 1 | Pages: 192-197

10.35680/2372-0247.1907 Get It

Engaging employees in providing exemplary patient experience has been challenging for healthcare leaders in recent years given the pressures of the regulatory environment, increases in staff burnout and rising patient expectations. Amid these challenges, addressing patient experience remains a top priority for healthcare organizations. A novel intervention has been applied at Mayo Clinic with the goal of improving both employee engagement and patient experience. Previous efforts to teach service excellence involved customer service trainings, sometimes purchased through outside vendors. This new initiative is based on our organizational culture and values, input from our employees and patients, and considers the changing needs of a contemporary healthcare workforce. It leverages management practices shown to boost an employee's sense of equity, achievement, and camaraderie. It also highlights staff motivation to do their best work by involving them in conversations about the essential ingredients that make up both exceptional employee and patient experiences.
Higher risk of recurrence in partially thrombosed cerebral aneurysms post-WEB (Woven EndoBridge) device treatment: insights from the WorldWideWEB Consortium registry
Saliou, Guillaume , Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Aslan, Assala , Swaid, Christian, Cuellar, Miguel, Dibas, Mahmoud , Cancelliere, Nicole M , Diestro, Jose Danilo Bengzon , Lay, Sovann V. , Guenego, Adrien , Möhlenbruch, Markus , Kral, Michael , Salem, Mohamed M , Foreman, Paul M. , Shaikh, Hamza , Župančić, Vedran , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Starke, Robert M. , Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios‐Nikos , Ulfert, Christian , Pukenas, Bryan , Burkhardt, Jan Karl, Slawski, Diana , Pulli, Benjamin , Lubicz, Boris , Puri, Ajit S , Pero, Guglielmo , Raz, Eytan , Asadi, Hamed , Siddiqui, Adnan H. , Haranhalli, Neil , Altschul, David , Ducruet, Andrew F. , Albuquerque, Felipe C , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula , Jabbour, Pascal , Clarençon, Frédéric , Patel, Aman B. , Salim, Hamza , Ghozy, Sherief , Lay, Sovann V , Guenego, Adrien , Carnevale, Joseph Anthony , ElNaamani, Kareem , Shotar, Eimad , Chung, Charlotte , Salem, Mohamed M , Lylyk, Ivan , Shaikh, Hamza A , Hafeez, Muhammad U , Catapano, Joshua S , Ren, Yifan , Schirmer, Clemens M , Michelozzi, Caterina , Hassan, Ameer E , Ogilvie, Mark , Nguyen, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Huynh, Thien J, Martinez-Gutierrez, Juan Carlos , Essibayi, Muhammed Amir , Sheth, Sunil A , Tawk, Rabih G , Pulli, Benjamin , Pero, Guglielmo , Raz, Eytan , Griessenauer, Christoph J , Siddiqui, Adnan H , Levy, Elad I , Albuquerque, Felipe C , Stapleton, Christopher , Kan, Peter , Kalousek, Vladimir , Tjoumakaris, Stavropoula , Cuellar-Saenz, Hugo H , Jabbour, Pascal , Dmytriw, Adam A , Hajdu, Steven D , Dibas, Mahmoud , Diestro, Jose Danilo B , Saliou, Guillaume , Altschul, David J , Musmar, Basel , Regenhardt, Robert W , Cancelliere, Nicole M , Ulfert, Christian , Burkhardt, Jan‐Karl , Cuellar, Miguel, Algin, Oktay , Ghozy, Sherief , Renieri, Leonardo , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Lylyk, Iván , Hafeez, Muhammad Ubaid , Waqas, Muhammad , Arslan, Muhammet , Ergün, Onur , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Huynh, Thien , Essibayi, Muhammed Amir , Tawk, Rabih G. , Panni, Pietro , Griessenauer, Christoph J. , Levy, Elad I. , Cuellar, Hugo , Limbucci, Nicola , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

Journal of NeuroInterventional Surgery | April 30, 2025 | Volume: 18 | Issue: 3 | Pages: 782-789

10.1136/jnis-2024-022628 | PMID 40306928 Get It

Background The Woven EndoBridge (WEB) device is a prevalent treatment for intracranial aneurysms. While many studies have assessed the obliteration rate post-WEB embolization, few have focused on long-term outcomes in partially thrombosed aneurysms. Objective To assess whether partially thrombosed aneurysms are at higher risk of recurrence or retreatment following WEB embolization compared with non-thrombosed aneurysms. Methods We evaluated data from 22 academic institutions, focusing on previously untreated cerebral aneurysms treated with the WEB device. Logistic regression was utilized to analyze factors predicting long-term aneurysm obliteration and retreatment necessity. Results Among 1303 patients, 26 presented with a partially thrombosed aneurysm. In the partially thrombosed group, the mean aneurysm maximal diameter was 10.7±4 mm with a neck ratio of 1.99±1.19 mm, larger than in the control group where the mean aneurysm maximal diameter was 6.81±2.37 mm with a neck ratio of 1.64±0.51 mm (P<0.001 for both maximal diameter and neck ratio). At the final follow-up, partially thrombosed aneurysms treated by the WEB device had a 38.5% retreatment rate, compared with 7.0% for non-thrombosed aneurysms (P<0.001). Among partially thrombosed aneurysms, the Raymond-Roy type IIIa/b occlusion rate was higher (38.5% vs 9.9%, P<0.001). On multivariate analysis, partially thrombosed aneurysms compared with non-thrombosed aneurysms had an increased rate of retreatment (OR 3.64, 95% CI 1.28 to 10.1). Conclusion Partially thrombosed aneurysms are associated with a poorer occlusion rate and a higher rate of retreatment following WEB embolization. For partially thrombosed aneurysms, the WEB device appears suboptimal as a first-line treatment, and therefore alternative techniques should be prioritized.
Dilated Cardiomyopathy Evaluation with Imagenomics: Combining Multimodal Cardiovascular Imaging and Genetics
Galanti, Kristian , Dabbagh, Ghaith Sharaf , Ricci, Fabrizio , Gallina, Sabina, Giansante, Roberta , Jacob, Ron , Obeng‐Gyimah, Edmond, Prasad, Sanjay , Birnie, David H. , Landstrom, Andrew P. , Mohammed, Selma F. , Landstrom, Andrew P , Mohammed, Selma , Mohiddin, Saidi , Khanji, Mohammed Yunus , Chahal, Choudhary Anwar A , Sharaf Dabbagh, Ghaith , Ricci, Fabrizio , Gallina, Sabina , Jacob, Ron, Cooper, Leslie T. , Prasad, Sanjay K , Khanji, Mohammed Y , Chahal, C. Anwar A.

Mayo Clinic

ESC Heart Failure | April 25, 2025 | Volume: 12 | Issue: 4 | Pages: 2669-2690

10.1002/ehf2.15307 | PMID 40275589 Get It

Abstract Dilated cardiomyopathy (DCM) is a clinical diagnosis characterized by the presence of left ventricular dilatation and systolic dysfunction unexplained by abnormal loading conditions or coronary artery disease. However, a broad range of phenotypic manifestations, encompassing isolated scar, DCM with preserved ejection fraction, and overt DCM, should be regarded as a diagnostic classification representing a broad spectrum of underlying aetiologies, including both inherited and acquired heart muscle disorders. A multimodal non-invasive imaging approach is essential for accurate morpho-functional assessment of cardiac chambers and is key to establish the cardiac phenotype and to rule out an underlying ischaemic aetiology. Furthermore, advanced imaging techniques enable deep cardiovascular phenotyping and non-invasive tissue characterization. The aim of this review is to propose a systematic approach to the diagnosis of DCM, emphasizing the importance of genetics and clinical findings for a precise and practical clinical approach. Also, we strive to qualify the role of cardiac imaging in the diagnosis of DCM, particularly on the relevance of novel techniques and clinical utility of actionable parameters to improve current diagnostic schemes and risk stratification algorithms. We further elaborate on the role of cardiac imaging to deliver optimal guidance to aetiology-based therapeutic approaches, verification of treatment response and disease progression monitoring.
Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries
Harris, Anne K. , Nelson, Alexander T. , Watson, Dave , Mallinger, Paige, Stering, Allen I., Snyder, Stacy L., Levy, Carolyn Fein , Kamihara, Junne , Herzog, Cynthia E. , Lagmay, Joanne , Foresto, Steve, Young, Robert H. , Dehner, Louis P. , Tadavarthy, Anil K., Stall, Jennifer N., Billmire, Deborah F., Schneider, Dominik T. , Schultz, Kris Ann P. , Kamihara, Junne , Chen, Kenneth S , Devins, Kyle M , Schneider, Dominik T , Schultz, Kris Ann P , Levy, Carolyn Fein , Harris, Anne K , Messinger, Yoav H. , Frazier, A Lindsay , Chen, Kenneth , Devins, Kyle M. , Hill, Dana Ashley

Mayo Clinic

Cancer | April 23, 2025 | Volume: 131 | Issue: 9 | Pages: No page available

10.1002/cncr.35862 | PMID 40267023 Get It

AbstractBackgroundOvarian juvenile granulosa cell tumors (juvGCT) are rare sex cord‐stromal tumors that occur primarily in children and adolescents. This study summarizes the clinical presentation and outcomes of patients with juvGCT.MethodsPatients were enrolled in the International Ovarian and Testicular Stromal Tumor and/or International Pleuropulmonary Blastoma/DICER1 Registries. Available medical records were abstracted, and pathology was centrally reviewed. Surgical staging was classified using the 2014 International Federation of Gynecology and Obstetrics (FIGO) criteria.ResultsIn total, 70 patients with juvGCT enrolled and were diagnosed between 2001 and 2024; most patients (81%, 57 of 70) presented with FIGO stage I disease. Adjuvant chemotherapy was given in 30% (21 of 70); all regimens were platinum‐based. Three‐year event‐free survival among patients with stage IA tumors was 80.2% (95% confidence interval [CI], 62.4%–100.0%), IC1 was 87.4 (95% CI, 72.4%–100.0%), IC2‐IC3 was 63.6% (95% CI, 40.7%–99.5%), and II‐IV was 48% (95% CI, 24.6%–93.8%). Of the patients with recurrent juvGCT with known mitotic index (MI), all had MI greater than 19 mitoses per 10 high power fields (HPF) at diagnosis.ConclusionOutcomes were worse for patients with FIGO stage ≥IC2 disease and for tumors with >19 mitoses per 10 HPF. Given the prognostic significance of MI, the authors strongly recommend the assessment of MI for all juvGCTs. More information about tumor biology is critical to identify which patients may benefit from adjuvant chemotherapy and to facilitate the development of novel therapies.